Literature DB >> 12628368

Latest development in viral vectors for gene therapy.

Kenneth Lundstrom1.   

Abstract

Gene therapy includes the application of various viral vectors, which represent most types and families of viruses, suitable for infection of mammalian host cells. Both hereditary diseases and acquired illnesses, such as cancer, can be targeted. Because of the various properties of each viral vector, the definition of their application range depends on factors such as packaging capacity, host range, cell- or tissue-specific targeting, replication competency, genome integration and duration of transgene expression. Recent engineering of modified viral vectors has contributed to improved gene delivery efficacy.

Entities:  

Mesh:

Year:  2003        PMID: 12628368     DOI: 10.1016/S0167-7799(02)00042-2

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  47 in total

1.  Gene delivery mediated by recombinant silk proteins containing cationic and cell binding motifs.

Authors:  Keiji Numata; Juliana Hamasaki; Balajikarthick Subramanian; David L Kaplan
Journal:  J Control Release       Date:  2010-05-10       Impact factor: 9.776

Review 2.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

Review 3.  Recent developments and current status of gene therapy using viral vectors in the United Kingdom.

Authors:  Kate Relph; Kevin Harrington; Hardev Pandha
Journal:  BMJ       Date:  2004-10-09

4.  The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.

Authors:  Timothy P O'Connor; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

Review 5.  Biological gene delivery vehicles: beyond viral vectors.

Authors:  Yiqi Seow; Matthew J Wood
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

6.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

7.  Diseases originate and terminate by genes: unraveling nonviral gene delivery.

Authors:  Rajan Swami; Indu Singh; Wahid Khan; Sistla Ramakrishna
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

8.  Spider silk-based gene carriers for tumor cell-specific delivery.

Authors:  Keiji Numata; Michaela R Reagan; Robert H Goldstein; Michael Rosenblatt; David L Kaplan
Journal:  Bioconjug Chem       Date:  2011-07-12       Impact factor: 4.774

9.  HIF1A overexpression using cell-penetrating DNA-binding protein induces angiogenesis in vitro and in vivo.

Authors:  Mijeong Jeon; Yooseok Shin; Jaeeun Jung; Ui-Won Jung; Jae-Hoon Lee; Jae-Seung Moon; Ilkoo Kim; Jin-Su Shin; Sang-Kyou Lee; Je Seon Song
Journal:  Mol Cell Biochem       Date:  2017-06-28       Impact factor: 3.396

10.  rna interference targeting p110β reduces tumor necrosis factor-alpha production in cellular response to wear particles in vitro and osteolysis in vivo.

Authors:  Jian-bin Huang; Yue Ding; Dong-sheng Huang; Wei-ke Zeng; Zhi-ping Guan; Mao-lin Zhang
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.